Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.58 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | RXRB | P28702 | 1/20 | 0.53 |
| ▸ | RXRG | P48443 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | CCKAR | P32238 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17077244 | 0.87 | ILK (0.52) | ALOX5PTGS2RXRARXRBRXRG | |
| SCHEMBL5382607 | 0.86 | PTGS2 (0.76) | ALOX5PTGS2RXRARXRBRXRG | |
| SCHEMBL23645857 | 0.86 | PTGS2 (0.56) | ALOX5PTGS2RXRARXRBRXRG | |
| SCHEMBL9207779 | 0.82 | CA9 (0.75) | PTGS2CA9PTGS1HTTL3MBTL1 | |
| SCHEMBL17077271 | 0.79 | HTT (0.47) | ALOX5CA9PTGS1ALDH1A1RAB9A | |
| SCHEMBL7239500 | 0.78 | MAPT (0.59) | PTGS2CA9CA1CA2PTGS1 | |
| SCHEMBL9522066 | 0.77 | PTGS2 (0.77) | ALOX5PTGS2RXRARXRBRXRG | |
| SCHEMBL9988889 | 0.77 | RXRA (0.66) | ALOX5PTGS2RXRARXRBRXRG | |
| SCHEMBL9695677 | 0.77 | RXRA (0.74) | ALOX5PTGS2RXRARXRBRXRG | |
| SCHEMBL27333015 | 0.77 | RPA1 (0.72) | PTGS2CA9PTGS1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117888-B2 | Irreversible inhibitors of pyruvate kinase M2 and the use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2021-09-14 | — | — | US | disclosed |
| US-20210221801-A1 | Irreversible inhibitors of pyruvate kinase M2 and the use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221801-A1 | Irreversible inhibitors of pyruvate kinase M2 and the use thereof | PDK2, PDK3, PDK4 | ALOX5 4072/4885PTGS2 617/4885RXRA 3747/4885 |
| US-11117888-B2 | Irreversible inhibitors of pyruvate kinase M2 and the use thereof | PDK2, PDK3, PDK4 | ALOX5 4072/4885PTGS2 617/4885RXRA 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.